WilmerHale Advises Alkermes in Acquisition of Rodin Therapeutics

WilmerHale Advises Alkermes in Acquisition of Rodin Therapeutics

News
On November 25, 2019, Alkermes plc announced the completion of its previously announced acquisition of Rodin Therapeutics, Inc., a privately held biopharmaceutical company focused on developing novel, small molecule therapeutics for synaptopathies. The WilmerHale team representing Alkermes was led by Stuart Falber, Joe Conahan and Mark Nylen and included Julie Hogan Rodgers, Scott Kilgore, Steve Barrett, Bruce Manheim, Barry Hurewitz, Hartmut Schneider, Paul Jakubowski, Ben Unger, Ben Kelsey, Lauren Ige, Meghan Fay and Meghan Muncey.